Cantor Fitzgerald Reaffirms “Overweight” Rating for BioDelivery Sciences International (NASDAQ:BDSI)

Cantor Fitzgerald reissued their overweight rating on shares of BioDelivery Sciences International (NASDAQ:BDSI) in a research report sent to investors on Monday morning, AnalystRatings.com reports. They currently have a $8.00 price objective on the specialty pharmaceutical company’s stock.

Several other analysts also recently commented on BDSI. Roth Capital reaffirmed a buy rating and set a $9.25 price objective on shares of BioDelivery Sciences International in a research note on Monday. ValuEngine raised BioDelivery Sciences International from a sell rating to a hold rating in a research note on Tuesday, February 25th. BidaskClub raised BioDelivery Sciences International from a sell rating to a hold rating in a research note on Saturday, May 9th. Northland Securities started coverage on BioDelivery Sciences International in a research note on Wednesday, April 22nd. They set an outperform rating and a $9.00 price objective for the company. Finally, Zacks Investment Research downgraded BioDelivery Sciences International from a buy rating to a hold rating and set a $4.50 price objective for the company. in a research note on Tuesday, March 10th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $8.11.

BioDelivery Sciences International stock opened at $4.79 on Monday. BioDelivery Sciences International has a fifty-two week low of $2.85 and a fifty-two week high of $7.21. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.94 and a current ratio of 2.19. The company has a market capitalization of $483.52 million, a P/E ratio of -53.22 and a beta of 0.77. The stock has a 50-day simple moving average of $4.49 and a 200-day simple moving average of $5.20.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $0.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.04. BioDelivery Sciences International had a positive return on equity of 23.61% and a negative net margin of 5.01%. The business had revenue of $38.28 million during the quarter, compared to the consensus estimate of $33.19 million. As a group, analysts forecast that BioDelivery Sciences International will post 0.19 earnings per share for the current year.

In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $5.07, for a total transaction of $507,000.00. Following the transaction, the director now owns 1,264,595 shares in the company, valued at approximately $6,411,496.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Francis E. Odonnell, Jr. sold 38,750 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $3.60, for a total value of $139,500.00. Following the transaction, the director now owns 611,254 shares in the company, valued at approximately $2,200,514.40. The disclosure for this sale can be found here. Insiders have sold a total of 349,249 shares of company stock worth $1,561,729 in the last quarter. 8.94% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank grew its holdings in shares of BioDelivery Sciences International by 1.7% in the 1st quarter. Swiss National Bank now owns 156,900 shares of the specialty pharmaceutical company’s stock worth $595,000 after acquiring an additional 2,600 shares during the period. Bank of Montreal Can grew its holdings in shares of BioDelivery Sciences International by 42.4% in the 4th quarter. Bank of Montreal Can now owns 10,436 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 3,108 shares during the period. Zebra Capital Management LLC grew its holdings in shares of BioDelivery Sciences International by 29.9% in the 1st quarter. Zebra Capital Management LLC now owns 16,693 shares of the specialty pharmaceutical company’s stock worth $63,000 after acquiring an additional 3,847 shares during the period. Aigen Investment Management LP acquired a new stake in shares of BioDelivery Sciences International in the 4th quarter worth approximately $27,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of BioDelivery Sciences International by 26.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 23,000 shares of the specialty pharmaceutical company’s stock worth $88,000 after acquiring an additional 4,800 shares during the period. Institutional investors and hedge funds own 73.64% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies.

Read More: What is Blockchain?

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit